Detection and Time to Treatment of Uveal Melanoma in the United Kingdom: An Evaluation of 2384 Patients

• Published in: Ophthalmology (Rochester, Minn.) Vol. 119; no. 8; pp. 1582 - 1589
• Main Authors: Damato, Erika M., MBBS, MRCP, Damato, Bertil E., MD, PhD
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.08.2012; Elsevier
• Subjects: Biological and medical sciences; Medical sciences; Miscellaneous; Ophthalmology; Tumors and pseudotumors of the eye, orbit, eyelid, lacrimal apparatus; United Kingdom; Europe; Human; Evaluation; Eye disease; Treatment; Uvea disease; Malignant tumor; Ophthalmology; Medical screening; Detection; Cancer; Uveal malignant melanoma
• ISSN: 0161-6420; 1549-4713
• DOI: 10.1016/j.ophtha.2012.01.048

Purpose To determine the mode of detection of uveal melanoma and time to treatment in the United Kingdom. Design Prospective cohort study. Participants A total of 2384 patients diagnosed with uveal melanoma at the Liverpool Ocular Oncology Center between 1996 and early 2011. Methods A questionnaire was completed with every new patient, and the results were correlated with clinical features and treatment. Main Outcome Measures Tumor detection, practitioner initiating referral, referral pathway, time to treatment, baseline clinical features, and primary ocular treatment. Results The referral process was initiated by an optometrist, family doctor, or ophthalmologist in 68.0%, 18.2%, and 13.8% of patients, respectively. On referral, 30.2% of patients were asymptomatic. Twenty-three percent of patients reported that their tumor was initially missed; these tended to have a more advanced tumor when they reached our center. The time from referral to treatment had a median of 49 days, exceeding 6 months in 19.8% of patients. This delay was longer in patients who reported that their tumor was missed (median, 92 vs. 40 days; Mann–Whitney, P <0.001). Ophthalmologists delayed the referral process by more than 6 months in 10.9% of patients. Primary enucleation was performed in 33.3% of patients and was more likely in those who reported that their tumor was missed (44.8% vs. 29.8%; chi-square, P <0.001). Conclusions Many patients with uveal melanoma experience long delays in treatment because their tumor was missed or misdiagnosed. Such patients tend to have a more advanced tumor by the time they reach an oncology center and are more likely to require enucleation. Financial Disclosure(s) The authors have no proprietary or commercial interest in any materials discussed in this article.